INHIBRX BIOSCIENCES INC

Inhibrx Biosciences (INBX) shares climb 3% to $97.1, valuing the company at $1.4B—outperforming peers as market dips 11% month‑to‑date.

Inhibrx Biosciences’ 6.14% rally may be a temporary spike—thin liquidity, high volatility and potential dilution risk signal investors to stay cautious.